Comparative Pharmacology
Head-to-head clinical analysis: BENTYL versus GLYCOPYRRONIUM TOSYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENTYL versus GLYCOPYRRONIUM TOSYLATE.
BENTYL vs GLYCOPYRRONIUM TOSYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicyclomine is a muscarinic acetylcholine receptor antagonist that blocks the action of acetylcholine at postganglionic parasympathetic effector sites, reducing gastrointestinal smooth muscle spasms and hypermotility.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3), inhibiting parasympathetic nerve impulses. Blocks the action of acetylcholine at autonomic effector sites innervated by postganglionic cholinergic nerves, reducing salivary, bronchial, and gastric secretions, and relaxing smooth muscle.
20 mg orally four times daily; may increase to 40 mg four times daily if tolerated. Immediate-release: 20 mg orally every 6 hours. Extended-release: 20 mg orally twice daily.
Glycopyrronium tosylate: 1-2 mg orally 2-3 times daily; maximum 8 mg daily.
None Documented
None Documented
1.9 to 3 hours (terminal elimination half-life); clinical context: short half-life supports multiple daily dosing for spasm relief.
Terminal elimination half-life: 0.6–1.2 hours in adults with normal renal function; prolonged in renal impairment (up to 3–4 hours). Clinically, duration of action is longer than half-life due to high receptor affinity.
Primarily renal (approximately 60% as unchanged drug and metabolites) and fecal (about 40% via biliary elimination).
Renal: 85% unchanged; biliary/fecal: ~5% as metabolites and unchanged drug; elimination primarily via glomerular filtration and tubular secretion.
Category C
Category C
Anticholinergic
Anticholinergic